Company Overview
Company Type: Public Company
Website: www.crescitatherapeutics.com
Number of Employees: -
Ticker: CTX (TSX)
Year Founded: 2016


Business Description
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers (MMPE) and DuraPeel for the development of topicals containing cannabis and hemp. The company’s prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud brand; and provides medical aesthetics under Pro-Derm and Alyria brands, for non-invasive and minimally invasive procedures or skincare treatments. In addition, it distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; and ART FILLER, hyaluronic acid-based dermal fillers. The company has a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
21.8
Market Capitalization
12.8
TEV/Total Revenue
0.2x
EBITDA
1.3
Total Enterprise Value
4.0
TEV/EBITDA
2.3x
EBIT
0.2
Cash & ST Invst.
10.2
P/Diluted EPS Before Extra
16.4x
Net Income
0.8
Total Debt
1.4
Price/Tang BV
0.7x
Capital Expenditure
0.0
Total Assets
26.5
Total Debt/EBITDA
0.8x
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
Verreault, Serge 
President, CEO & Director
DaRocha, Jose 
Chief Financial Officer
Lafortune, Francois 
Executive VP & GM

Key Board Members
Name
Title
Chicoine, Daniel N.
Non-Executive Chairman
Verreault, Serge 
President, CEO & Director
London, John C.
Independent Vice Chairman
Dobranowski, Anthony E.
Independent Lead Director
Shannon-Trudeau, Deborah 
Independent Non-Executive Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
2805 Place Louis-R Renaud | Laval, QC | H7V 0A3 | Canada

Current and Pending Investors
Bloom Burton & Co., Investment Arm, Bloom Burton Healthcare Lending Trust, Stratigis Capital Advisors Inc.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.63
Market Cap (mm)
12.8
Open
 0.63
Shares Out. (mm)
20.4
Previous Close
 0.63
Float %
89.4%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.63/ 0.63
Diluted EPS Excl. Extra Items
0.04
52 wk High/Low
 0.79/ 0.50
P/Diluted EPS Before Extra
16.39x
Volume (mm)
0.0030
Avg 3M Dly Vlm (mm)
0.02
Beta 5Y
1.92


 
Delayed Quote** | Last Updated on Oct-06-2023 09:48 AM (GMT-5)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
INTEGA Skin Sciences Inc.
INTEGA Skin Sciences Inc. manufactures pharmaceuticals for the treatment and care of skin diseases and their symptoms. It offers dermatology products. The company has a strategic agreement with Valeant Groupe Cosméderme. INTEGA Skin Sciences Inc. was founded in 2015 and is headquartered in Montreal, Canada. As of September 1, 2016, INTEGA Skin Sciences Inc. operates as a subsidiary of Crescita Therapeutics Inc.

United States and Canada
Pharmaceuticals
-
-
-
Akyucorp Ltd.
Akyucorp Ltd. owns and operates aesthetic clinics and provides cosmetic medical, laser, and surgical services. The company was founded in 2002 and is based in Owen Sound, Canada.

United States and Canada
Health Care Facilities
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-29-2023
-
Buyback
Target
Crescita Therapeutics Inc. (TSX:CTX)


-
Mar-15-2023
Oct-31-2022
Merger/Acquisition
Buyer
Akyucorp Ltd.
Crescita Therapeutics Inc. (TSX:CTX)

0.04
Dec-15-2021
-
Buyback
Target
Crescita Therapeutics Inc. (TSX:CTX)


0.77
Sep-07-2021
Sep-07-2021
Merger/Acquisition
Buyer
Akyucorp Ltd.
Crescita Therapeutics Inc. (TSX:CTX)

0.26
Nov-26-2020
-
Buyback
Target
Crescita Therapeutics Inc. (TSX:CTX)


0.07
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-29-2023
Buyback Transaction Announcements
Crescita Therapeutics Inc. (TSX:CTX) announces an Equity Buyback for 1,821,616 shares, representing 8.94% of its issued share capital.
Aug-29-2023
Buyback Transaction Announcements
Crescita Therapeutics Inc. authorizes a Buyback Plan.
Jun-20-2023
Annual General Meeting
Crescita Therapeutics Inc., Annual General Meeting, Jun 20, 2023
Jun-01-2023
Business Expansions
Crescita Therapeutics Inc. Announces Launch of Topical Anaesthetic Pliaglis(R) in Europe in Its European Core Markets Including Germany, the United Kingdom and Ireland
Mar-15-2023
Buyback Tranche Update
Tranche Update on Crescita Therapeutics Inc. (TSX:CTX)'s Equity Buyback Plan announced on December 15, 2021.


Advisors
Most Recent Auditor
Ernst & Young LLP
Public Offering Advisors
Goodmans LLP, Troutman Pepper Hamilton Sanders LLP


Most Recent Auditor
Ernst & Young LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 03:58 AM
CTX
Crescita Therapeutics Inc 2023_10_05
Reports
15
GlobalData

Sep 15, 2023 02:13 AM
CTX
Crescita Therapeutics Inc (CTX.TSE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
22
MarketLine

Sep 14, 2023 06:01 AM
CTX
Crescita Therapeutics Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
97
GlobalData

Sep 13, 2023 02:02 AM
CTX
Crescita Therapeutics Inc (CTX.TSE) - Financial Analysis Review
Reports
158
S&P Global Compustat

Sep 07, 2023 03:56 AM
CTX
Crescita Therapeutics Inc 2023_09_07
Reports
15
GlobalData

Aug 29, 2023 01:53 AM
CTX
Crescita Therapeutics Inc (CTX.TSE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
42
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Jul 25, 2023 06:00 PM
CTX
Rating Update for Crescita Therapeutics Inc
EPS Estimates*
3
S&P Global Compustat

Jul 06, 2023 03:26 AM
CTX
Crescita Therapeutics Inc 2023_07_06
Reports
15
GlobalData

Jun 14, 2023 05:00 AM
CTX
Crescita Therapeutics Inc (CTX.TSE) - Financial Analysis Review
Reports
158
GlobalData

Jun 09, 2023 02:30 AM
CTX
Crescita Therapeutics Inc (CTX.TSE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
24


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Chicoine B.Com., B.Comm., C.A., CPA, CA, CPA, Daniel N.

1,057,377

5.19

0.7

Apr-24-2023


Verreault B.A., M.B.A., Serge 

661,151

3.25

0.4

Aug-31-2023


London L.L.B., L.L.M., LLB, LLM, John C.

193,522

0.95

0.1

Apr-24-2023


DaRocha C.A., CPA, Jose 

106,558

0.52

0.1

Aug-31-2023


Dobranowski B.A., B.Sc., BA, C.A., C.P.A., CA, CPA, M.B.A., MB, Anthony E.

100,000

0.49

0.1

Apr-24-2023


Hull, Wade A.

39,384

0.19

0.0

Aug-31-2023


Copeland BMath, C.A., C.P.A., CA, CPA, David Alexander

0

0.00

0.0

Jun-20-2023


Schlader B.Sc., BSc, Thomas 

0

0.00

0.0

Jun-20-2023



 



Top Buyers
No Top Buyers data available.

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Copeland BMath, C.A., C.P.A., CA, CPA, David Alexander
0
(95,427)
Schlader B.Sc., BSc, Thomas 
0
(36,681)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Alyria, Art-Filler Injectables, Contract Manufacturing and Development Services, CTX-101 (Future), CTX-102 (Future), Dermazulene, Distribution of Obagi Medical, Flexicaine (Future), Laboratoire Dr Renaud, Licensing of MMPE Technology, Licensing of Peel and DuraPeel Technologies, Licensing of Pliaglis, New Cellular Treatment Factor, Pliaglis, Pro-Derm


Upcoming Events
Date/Time
Type
Nov-10-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Aug-09-2023
Jun-30-2023
Crescita Therapeutics Inc. (TSX:CTX)
SEDAR
Interim Financial Statements
407 KB
Aug-09-2023
-
Crescita Therapeutics Inc. (TSX:CTX)
SEDAR
News Releases
224 KB
Jun-21-2023
-
Crescita Therapeutics Inc. (TSX:CTX)
SEDAR
News Releases
165 KB
Jun-21-2023
-
Crescita Therapeutics Inc. (TSX:CTX)
SEDAR
Management Proxy Materials
121 KB
May-11-2023
Mar-31-2023
Crescita Therapeutics Inc. (TSX:CTX)
SEDAR
Interim Financial Statements
351 KB
May-11-2023
-
Crescita Therapeutics Inc. (TSX:CTX)
SEDAR
News Releases
176 KB
May-10-2023
-
Crescita Therapeutics Inc. (TSX:CTX)
SEDAR
Management Proxy Materials
758 KB
May-10-2023
-
Crescita Therapeutics Inc. (TSX:CTX)
SEDAR
Management Proxy Materials
129 KB
May-10-2023
-
Crescita Therapeutics Inc. (TSX:CTX)
SEDAR
Management Proxy Materials
72 KB
Apr-06-2023
Dec-31-2022
Crescita Therapeutics Inc. (TSX:CTX)
SEDAR
Annual Report
3 MB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Dobranowski B.A., B.Sc., BA, C.A., C.P.A., CA, CPA, M.B.A., MB, Anthony E. (Independent Lead Director)
Aug-16-2022
Common Shares
15,638
11,419
Open Market Acquisition
18.54
Multiple
Dobranowski B.A., B.Sc., BA, C.A., C.P.A., CA, CPA, M.B.A., MB, Anthony E. (Independent Lead Director)
Aug-16-2022
Common Shares
(15,638)
(10,599)
Open Market Disposition
(13.52)
Multiple
-
Aug-16-2022
Common Shares
(1,538)
(1,046)
Open Market Disposition
-
Exchange Announcement
-
Aug-16-2022
Common Shares
(14,100)
(9,553)
Open Market Disposition
-
Exchange Announcement
Chicoine B.Com., B.Comm., C.A., CPA, CA, CPA, Daniel N. (Non-Executive Chairman)
Dec-15-2021
Common Shares
11,900
8,241
Open Market Acquisition
1.14
Multiple
-
Dec-15-2021
Common Shares
5,000
3,602
Open Market Acquisition
-
Exchange Announcement
-
Dec-15-2021
Common Shares
3,400
2,341
Open Market Acquisition
-
Exchange Announcement
-
Dec-15-2021
Common Shares
3,500
2,299
Open Market Acquisition
-
Exchange Announcement
Verreault B.A., M.B.A., Serge  (President, CEO & Director)
Dec-15-2021
Common Shares
11,800
8,014
Open Market Acquisition
1.82
Multiple
-
Dec-15-2021
Common Shares
300
207
Open Market Acquisition
-
Exchange Announcement
-
Dec-15-2021
Common Shares
1,000
689
Open Market Acquisition
-
Exchange Announcement
-
Dec-15-2021
Common Shares
2,000
1,377
Open Market Acquisition
-
Exchange Announcement
-
Dec-15-2021
Common Shares
5,000
3,443
Open Market Acquisition
-
Exchange Announcement
-
Dec-15-2021
Common Shares
3,000
1,970
Open Market Acquisition
-
Exchange Announcement
-
Dec-15-2021
Common Shares
500
328
Open Market Acquisition
-
Exchange Announcement
DaRocha C.A., CPA, Jose  (Chief Financial Officer)
Dec-15-2021
Common Shares
6,000
4,020
Open Market Acquisition
5.97
Multiple
-
Dec-15-2021
Common Shares
2,500
1,721
Open Market Acquisition
-
Exchange Announcement
-
Dec-15-2021
Common Shares
3,500
2,299
Open Market Acquisition
-
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Chicoine, Daniel N.
Non-Executive Chairman
-
-

Verreault, Serge 
President, CEO & Director
-
-

London, John C.
Independent Vice Chairman
-
-

Dobranowski, Anthony E.
Independent Lead Director
-
-

Shannon-Trudeau, Deborah 
Independent Non-Executive Director
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Verreault, Serge 
President, CEO & Director
-
-

DaRocha, Jose 
Chief Financial Officer
-
-

Lafortune, Francois 
Executive VP & GM
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
